Fabien Vincent

Fabien Vincent, PhD is a senior drug discovery scientist with experience as both an in vitro pharmacology group leader and a drug discovery project leader. He gained expertise in pharmacology at Pfizer (2010-2025) as a laboratory head in the Primary Pharmacology Group. There, his laboratory supported the small molecule portfolio of the Immunology & Inflammation research unit, helping deliver 15 clinical candidates with two becoming FDA approved drugs so far (Abrocitinib, Ritlecitinib). His remit spanned target identification & validation, designing and executing hit identification & validation strategies, structure-activity relationships (SAR) support, mechanistic studies and study reports for the FDA. His main research interests are centered on drugging tough-but-well-validated targets and improving the translation of preclinical research to patients using physiologically relevant assays and phenotypic screening.